With initial funding from the National Institute of Aging and as part of NIA’s large initiatives Advancing Medicines Partnership (AMP-AD) and Molecular Mechanisms of Vascular Etiology (M2OVE-AD), we have established the Alzheimer Disease Metabolomics Consortium (ADMC). The ADMC brings together centers of excellence of metabolomics, informatics and modeling to work collaboratively with Alzheimer’s Disease experts to map metabolic failures across the trajectory of disease. We implement a systems approach advocated in the recommendations of the Alzheimer’s Summits of 2012 and 2015, where metabolomics data is used to inform and complement genomics, proteomics, and neuroimaging data to provide novel insights about disease mechanisms. Metabolomics data captures influences of the environment, the diet, the gut microbiome, the exposome on metabolic states that affect brain health. We connect peripheral and central metabolic changes to define blood biomarkers that inform about disease and progression and we create a biochemical roadmap for novel drug discovery.